CHAPTER 67

Tuberculosis

Brit Long
Alex Koyfman

REFERENCES

1. Blanc FX, Sok T, Laureillard D, et al: Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. *N Engl J Med* 365: 1471, 2011. [PMID: 22010913]
2. World Health Organization: *Global tuberculosis control. WHO report*. Geneva, Switzerland: World Health Organization, 2011.
3. Centers for Disease Control and Prevention: Trends in tuberculosis—United States, 2011. *MMWR* 61: 181, 2012. [PMID: 22437911]
4. Linas BP, Wong AY, Freedberg KA, et al: Priorities for screening and treatment of latent tuberculosis infection in the United States. *Am J Respir Crit Care Med* 184: 590, 2011. [PMID: 21562129]
5. Dheda K, Barry CE, Maartens G. Tuberculosis. *Lancet* 387: 1211, 2016. [PMID: 26377143]
6. Schlossberg D: Acute tuberculosis. *Infect Dis Clin N Am* 24: 139, 2010. [PMID: 20171549]
7. Horsburgh CR, O'Donnell M, Chamblee S, et al: Revisiting rates of reactivation tuberculosis: a population-based approach. *Am J Respir Crit Care Med* 182: 420, 2010. [PMID: 20395560]
8. Horsburgh CR, Rubin EJ: Latent tuberculosis infection in the United States. *N Engl J Med* 364: 1441, 2011. [PMID: 21488766]
9. Brassard P, Suissa S, Kezouh A, Ernst P: Inhaled corticosteroids and risk of tuberculosis in patients with respiratory diseases. *Am J Respir Crit Care Med* 183: 675, 2011. [PMID: 20889902]
10. Kardos M, Kinball AB: Time for a change? Updated guidelines using interferon gamma release assays for detection of latent tuberculosis in the office setting. *J Am Acad Dermatol* 66: 148, 2012. [PMID: 22177633]
11. Moran GJ, McCabe F, Morgan MT, Talan DA: Delayed recognition and infection control for tuberculosis patients in the emergency department. *Ann Emerg Med* 26: 290, 1995. [PMID: 7661416]
12. http://www.cdc.gov/tb/ (Centers for Disease Control and Prevention: Tuberculosis.) Accessed October 26, 2018.
13. Reichler MR, Khan A, Sterling TG, et al: Risk and timing of tuberculosis among close contacts of persons with infectious tuberculosis. *J Infect Dis* 218: 1000, 2018. [PMID: 29767733]
14. Further studies of geographic variation in naturally acquired tuberculin sensitivity. *Bull World Health Organ* 12: 63, 1955. [PMID: 14351968]
15. Centers for Disease Control and Prevention: Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection—United States, 2010. *MMWR* 59: 1, 2010. [PMID: 20577159]
16. Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K: Updated guidelines for using interferon gamma release assays to detect *Mycobacterium tuberculosis* infection: United States, 2010. *MMWR Recomm Rep* 59: 1, 2010. [PMID: 20577159]
17. Manuel O, Humar A, Preiksaitis J, et al: Comparison of quantiferon-TB gold with tuberculin skin test for detecting latent tuberculosis infection prior to liver transplantation. *Am J Transplant* 12: 2797, 2007. [PMID: 17941955]
18. Mazurek GH, Weis SE, Moonan PK, et al: Prospective comparison of the tuberculin skin test and 2 whole-blood interferon-gamma release assays in persons with suspected tuberculosis. *Clin Infect Dis* 45: 837, 2007. [PMID: 17806047]
19. Froeschle JE, Ruben FL, Bloh AM: Immediate hypersensitivity reactions after use of tuberculin skin testing. *Clin Infect Dis* 34: E12, 2002. [PMID: 11731966]
20. Menzies D, Pai M, Comstock G: Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. *Ann Intern Med* 146: 340, 2007. [PMID: 17339619]
21. Pai M, Zwerling A, Menzies D: Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. *Ann Intern Med* 149: 177, 2008. [PMID: 18593687]
22. Centers for Disease Control and Prevention: Treatment of tuberculosis: practice guidelines for treatment of tuberculosis. *MMWR* 52: No. RR-11, 2003. [PMID: 12836625]
23. Metcalfe JZ, Everett CK, Steingart KR, et al: Interferon-γ release assays for active pulmonary tuberculosis diagnosis in adults in low- and middle-income countries: systematic review and meta-analysis. *J Infect Dis* 204(suppl 4): S1120, 2011. [PMID: 21996694]
24. Sester M, Sotgiu G, Lange C, et al: Interferon-γ release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. *Eur Respir J* 37: 100, 2011. [PMID: 20847080]
25. Lange C, Mori T: Advances in the diagnosis of tuberculosis. *Respirology* 15: 220, 2011. [PMID: 20199641]
26. Yoo S, Cattamanchi A, Den Boon S, et al: Clinical significance of normal radiographs among HIV-seropositive patients with suspected tuberculosis in Uganda. *Respirology* 16: 836, 2011. [PMID: 21518124]
27. Sterling T, Pham P, Chaisson R: HIV infection-related tuberculosis: clinical manifestations and treatment. *Clin Infect Dis* 50 (Suppl 3): S223, 2010. [PMID: 20397952]
28. Cruciani M, Scarparo C, Malena M, et al: Meta-analysis of BACTEC MGIT 960 and BACTEC 460 TB, with or without solid media, for detection of mycobacteria. *J Clin Microbiol* 42: 2321, 2004. [PMID: 15131224]
29. Cheng VC, Yew WW, Yuen KY: Molecular diagnostics in tuberculosis. *Eur J Clin Microbiol Infect Dis* 24: 711, 2005. [PMID: 16283213]
30. Catanzaro A, Perry S, Clarridge JE, et al: The role of clinical suspicion in evaluating a new diagnostic test for active tuberculosis: results of a multicenter prospective trial. *JAMA* 283: 639, 2000. [PMID: 10665704]
31. Conaty SJ, Claxton AP, Enoch DA, et al: The interpretation of nucleic acid amplification tests for tuberculosis: do rapid tests change treatment decisions? *J Infect* 50: 187, 2005. [PMID: 15780411]
32. Lim TK, Mukhopadhyay A, Gough A, et al: Role of clinical judgment in the application of a nucleic acid amplification test for the rapid diagnosis of pulmonary tuberculosis. *Chest* 124: 902, 2003. [PMID: 12970015]
33. Wiener RS, Della-Latta P, Schluger NW: Effect of nucleic acid amplification for *Mycobacterium* tuberculosis on clinical decision making in suspected extrapulmonary tuberculosis. *Chest* 128: 102, 2005. [PMID: 16002922]
34. http://who.int/tb/features_archive/Xpert-Ultra/en/. (World Health Organization) Next-generation Xpert® MTB/RIF Ultra assay recommended by WHO.) Accessed June 10, 2018.
35. Dinnes J, Deeks J, Kunst H, et al: A systematic review of rapid diagnostic tests for the detection of tuberculosis infection. *Health Technol Assess* 11: 1, 2007. [PMID: 17266837]
36. Centers for Disease Control and Prevention (CDC): Updated guidelines for the use of nucleic acid amplification tests in the diagnosis of tuberculosis. *MMWR Morb Mortal Wkly Rep* 58: 7, 2009. [PMID: 19145221]
37. Choi JH, Lee KW, Kang HR, et al: Clinical efficacy of direct DNA sequencing analysis on sputum specimens for early detection of drug-resistant *Mycobacterium* tuberculosis in a clinical setting. *Chest* 137: 393, 2010. [PMID: 19741059]
38. http://www.who.int/tb/publications/use-of-lf-lam-tb-hiv/en/. (World Health Organization: The use of lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis and screening of active tuberculosis in people living with HIV: Policy update.) Accessed June 10, 2018.
39. Nahid P, Dorman SE, Alipanah N, et al: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of drug-susceptible tuberculosis. *Clin Infect Dis* 63: e147, 2016. [PMID: 27516382]
40. Johnson JL, Hadad DJ, Dietze R, et al: Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. *Am J Respir Crit Care Med* 180: 558, 2009. [PMID: 19542476]
41. Kruk ME, Schwalbe NR, Aguiar CA: Timing of default from tuberculosis treatment: a systematic review. *Trop Med Int Health* 13: 703, 2008. [PMID: 18266783]
42. http://apps.who.int/iris/bitstream/10665/255052/1/9789241550000-eng.pdf?ua=1. (World Health Organization: Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 update.) Accessed June 10, 2018.
43. Saukkonen JJ, Cohn DL, Jasmer RM, et al: An official ATS statement: hepatotoxicity of antituberculosis therapy. *Am J Respir Crit Care Med* 174: 935, 2006. [PMID: 17021358]
44. Swaminathan S, Padmapriyadarsini C, Narendran G: HIV-associated tuberculosis: clinical update. *Clin Infect Dis* 50: 1377, 2010. [PMID: 20388036]
45. Ferebee SH, Mount FW: Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts. *Am Rev Respir Dis* 85: 490, 1962. [PMID: 13892318]
46. http://en.sanofi.com/Images/37707_20141202_priftin_en.pdf. (Sanofi: Sanofi receives FDA approval of Priftin® [Rifapentine] tablets for the treatment of latent tuberculosis infection.) Accessed December 10, 2014.
47. Sterling TR, Villarino ME, Borisov AS, et al: Three months of rifapentine and isoniazid for latent tuberculosis infection. *N Engl J Med* 365: 2155, 2011. [PMID: 22150035]
48. Centers for Disease Control and Prevention: Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent *Mycobacterium tuberculosis* infection. *MMWR* 60: 1650, 2011. [PMID: 22157884]
49. Tuberculosis control laws–United States, 1993. Recommendations of the Advisory Council for the Elimination of Tuberculosis (ACET). *MMWR Recomm Rep* 42: 1, 1993. [PMID: 8145707]
50. Sotir MJ, Parrott P, Metchock B, et al: Tuberculosis in the inner city: impact of a continuing epidemic in the 1990s. *Clin Infect Dis* 29: 1138, 1999. [PMID: 10524954]
51. Sonnenberg P, Glynn JR, Fielding K, Murray J, Godfrey-Faussett P, Shearer S: How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. *J Infect Dis* 191: 150, 2005. [PMID: 15609223]
52. World Health Organization: *Global Tuberculosis Report WHO*. Geneva, Switzerland: World Health Organization; 2014.
53. Kwan CK, Ernst JD: HIV and tuberculosis: a deadly human syndemic. *Clin Microbiol Rev* 24: 351, 2011. [PMID: 21482729]
54. Cohen K, Meintjes G: Management of individuals requiring antiretroviral therapy and tuberculosis treatment. *Curr Opin HIV AIDS* 5: 61, 2010. [PMID: 20046149]
55. Torok ME, Farrar JJ: When to start antiretroviral therapy in HIV-associated tuberculosis. *N Engl J Med* 365: 1538, 2011. [PMID: 22010921]
56. American Thoracic Society: Targeted tuberculin testing and treatment of latent tuberculosis infection. *MMWR Recomm Rep* 49: 1, 2000. [PMID: 10881762]
57. http://www.cdc.gov/tb/publications/factsheets/drtb/xdrtb.htm. (Centers for Disease Control and Prevention: Extensively drug-resistant tuberculosis [XDR TB]). Accessed June 10, 2018.
58. Centers for Disease Control and Prevention: Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force. *MMWR Recomm Rep* 58: 1, 2009. [PMID: 19214162]
59. Kant S, Maurya A, Kushwaha RA, et al: Multi-drug resistant tuberculosis: an iatrogenic problem. *Biosci Trends* 4: 48, 2010. [PMID; 20448341]

60. http://www.who.int/tb/challenges/mdr/tdrfaqs/en/index.html. (World Health Organization: Drug-resistant tuberculosis.) Accessed June 10, 2018.
61. World Health Organization: Antituberculosis drug resistance in the world. The WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance. Geneva, Switzerland: World Health Organization; 2008.
62. Gler MT, Skripconoka V, Sanchez-Garavito E, et al: Delamanid for multidrug-resistant pulmonary tuberculosis. *N Engl J Med* 366: 2151, 2012. [PMID: 22670901]
63. https://www.janssen.com/us/. (Sirturo (bedaquiline) prescribing information [package insert]. Titusville, NJ: Janssen Therapeutics, Division of Johnson & Johnson.) Accessed October 26, 2018.
64. http://www.medscape.com/viewarticle/776901. (Tucker ME: FDA approves bedaquiline for resistant TB treatment. Medscape Medical News. December 31, 2012.) Accessed June 10, 2018.
65. Diacon AH, Pym A, Grobusch M, et al: The diarylquinoline TMC207 for multidrug-resistant tuberculosis. *N Engl J Med* 360: 2397, 2009. [PMID: 19494215]
66. Swaminathan S, Rekha B: Pediatric tuberculosis: global overview and challenges. *Clin Infect Dis* 50 (Suppl 3): S173, 2010. [PMID: 20397947]
67. Connell TG, Zar HJ, Nicol MP: Advances in the diagnosis of pulmonary tuberculosis in HIV-infected and HIV-uninfected children. *J Infect Dis* 204 (Suppl 4): S1151, 2011. [PMID: 21996697]
68. Nicol MP, Zar HJ: New specimens and laboratory diagnostics for childhood pulmonary tuberculosis: progress and prospects. *Paediatr Resp Rev* 12: 16, 2011. [PMID: 21172670]
69. Furqan M, Butler J: Miliary pattern on chest radiography: tuberculosis or not tuberculosis? *Mayo Clin Proc* 85: 108, 2010. [PMID: 20118384]
70. Thwaites GE, van Toorn R, Schoeman J: Tuberculous meningitis: more questions, still too few answers. *Lancet Neurol* 12: 999, 2013. [PMID: 23972913]